Provided by Tiger Trade Technology Pte. Ltd.

JUNSHI BIO

17.460
-0.430-2.40%
Volume:2.04M
Turnover:36.31M
Market Cap:17.93B
PE:-20.07
High:18.500
Open:18.400
Low:17.320
Close:17.890
52wk High:31.800
52wk Low:15.250
Shares:1.03B
HK Float Shares:260.00M
Volume Ratio:2.18
T/O Rate:0.79%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.870
ROE:-9.32%
ROA:-2.89%
PB:2.58
PE(LYR):-20.07
PS:5.06

Loading ...

AH Premium Rankings for August 27: A Market Overview

Stock News
·
Aug 27

Shanghai Junshi Biosciences Estimates 35 Million Yuan in Related-Party Transactions

MT Newswires Live
·
Aug 27

Press Release: Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Dow Jones
·
Aug 27

Junshi Biosciences Reports First-Half Net Profit of RMB21.66 Million, Reversing Year-Earlier Loss

Stock News
·
Aug 27

Junshi Bio Terminates 2026 A-Share Employee Stock Ownership Scheme

Bulletin Express
·
Aug 26

Shanghai Junshi Biosciences Return to Profit in H1

MT Newswires Live
·
Aug 26

Junshi Bio Turns Profitable as H1 2026 Revenue Leaps 45% to RMB1.70 Billion on Strong TUOYI® Momentum

Bulletin Express
·
Aug 26

Junshi Biosciences Swings to Profit in First-Half Results

Stock News
·
Aug 26

Junshi Biosciences Raises 700 Million Yuan Through Tech Innovation Bond Issuance

Stock News
·
Aug 21

Shareholder Offloads Nearly 7 Billion Yuan in Precision-Timed Selloff, Stake Drops to 3.79%

Deep News
·
Aug 21

JUNSHI BIO Sets 26 August 2026 Board Meeting to Review 1H 2026 Results

Bulletin Express
·
Aug 12

Junshi Biosciences Shareholder Cuts Stake

MT Newswires Live
·
Aug 11

JUNSHI BIO Shareholder He Ming Completes Sale of 882,600 Shares, Fulfilling Reduction Plan

Stock News
·
Aug 10

Junshi Biosciences Completes 300 Million Yuan Second Tranche Bond Issue

MT Newswires Live
·
Jul 23

Shanghai Junshi's Toripalimab Supplemental Application Accepted in China

MT Newswires Live
·
Jul 22

Shanghai Junshi Biosciences Gets NMPA Acceptance Notice of Supplemental Application for Toripalimab

Reuters
·
Jul 22

Shanghai Junshi Biosciences - Acceptance of Supplemental Application for Toripalimab in Combination with Chemotherapy as Perioperative Treatment

THOMSON REUTERS
·
Jul 21

Shanghai Junshi Biosciences - Acceptance Notice Issued by Nmpa China

THOMSON REUTERS
·
Jul 21

Zhongou Fund's Ge Lan Q2 Report Revealed: Junshi Bio Enters Top Holdings, Kelun Pharma Sees Major Increase

Deep News
·
Jul 21

HK Movers | Biomedical Stocks Rally; REMEGEN, WUXI XDC and KEYMED BIO-B Surge Over 8%

Tiger Newspress
·
Jul 20